Metabolic Consequences of Cross-sex Hormonal Treatment

Study Overview
=================
Brief Summary
-----------------
Retrospective study in a single academic regional transgender referral center. Analyse VAT, body composition and metabolic parameters in non-obese transgender subjects one year after starting gender-affirming hormone therapy and in controls

Official Title
-----------------
Metabolic Consequences of Cross-sex Hormonal Treatment in Transgender Persons

Conditions
-----------------
Gender Dysphoria

Intervention / Treatment
-----------------
* Other: Gender-affirming hormone therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria (retrospective analysis of available data as a part of the regular care of subjects with gender dysphoria. All measurements were made at the time of the routine follow-up visits) age >= 16 years (Tanner stage IV) and <= 50 years at the initiation of gender-affirming hormone therapy; BMI < 28 kg/m2 at the initiation of cross-sex hormonal treatment. Exclusion Criteria: hormonal contraception previous gender-affirming hormonal treatment previous gender-affirming surgery recognized syndrome or chromosomal defect, known metabolic or inflammatory disease, skeletal dysplasia, or chronic corticosteroid treatment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hormonal treatment<br>The University Hospital in Nancy is an academic regional transgender referral center in Lorraine (France) and keeps a register of subjects available from 2004. The register at the time of the present study (February 2020) included 320 subjects who met diagnostic criteria for gender dysphoria and were seen regularly in the out-patient clinic at our department of endocrinology. Our investigation is a part of the regular care of subjects with gender dysphoria. | Other: Gender-affirming hormone therapy<br>* Gender-affirming hormone therapy according to the recommendations of the Endocrine Society<br>|
| Controls<br>Data for control subjects are retrieved from medical records of healthy non-obese females and males who underwent an initial assessment for gender dysphoria in our department, but not yet receiving hormonal treatment at the time of the present study. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective analysis of existing data collected as a part of the regular follow-up | Retrospective analysis of existing data :Anthropometric parameters, including systolic blood pressure (SBP), diastolic blood pressure (DBP), body weight and height at fasting state, were measured in all subjects at the occasion of the routine follow-up visits. Body mass index (BMI) was calculated as body weight in kilograms divided by the height in meter squared (kg/m2). Body composition parameters, including lean mass (LM), total body fat (BF), android and gynoid fat, and bone mineral content, were determined using dual-energy X-Ray absorbtiometry (DXA) (GE-Healthcare Lunar iDXA system), biochemical and routine hormonal analysis | Retrospective analysis of data between 2004 and 2019 |